The Science of BerGenBio

BerGenBio is committed to developing innovative drugs for immune-evasive, drug resistant, metastatic cancers. The company is a world-leader in understanding the biology of the epithelial-mesenchymal transition (EMT). This natural cellular programme is, when it occurs inappropriately, implicated in the development of immune-evasion and acquired drug-resistance in cancer cells. When EMT is inhibited with BerGenBio's drug candidates the cancer cells become visible and sensitive to the body's immune system and the effectiveness of commonly used cancer drugs is restored.

Explore the science of BerGenBio